Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Nucor Corporation (NUE) Price & Performance

Eli Lilly And CoTrade
Nucor CorporationTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Nucor Corporation — how do they compare? Eli Lilly And Co trades at $1,220.04 (market cap $1.08T), while Nucor Corporation trades at $272.26 (market cap $61.93B). The key difference: Eli Lilly And Co is far larger — about 17.4× Nucor Corporation's market cap, and Nucor Corporation pays the higher dividend (0.82%). Which is the better fit depends on your goals.

LLYNUE
Market Cap
$1.08T$61.93B
Sector
HealthBasic Materials
52-Week High
$1.24K$274.74
52-Week Low
$639.43$131.78
Enterprise Value
$1.13T$66.34B
Dividend Yield
0.57%0.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Nucor Corporation

Nucor (NUE) trades at $269.50, down 1.86% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings with EPS of $4.84 beating estimates of $4.46, driven by record steel mill shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections indicating $36.1B revenue and improved margins. Analyst consensus remains positive with 59% buy ratings and a $279.63 price target, representing 3.8% upside potential.

Nucor presents a compelling investment case with earnings momentum, favorable analyst sentiment, and technical strength. Key opportunities include continued demand recovery and operational efficiency gains. However, risks include cyclical steel industry exposure, tariff policy uncertainties, and declining operating cash flow trends from 2022 peaks. The stock offers moderate upside to consensus targets but faces macroeconomic headwinds affecting industrial demand.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Nucor Corporation

Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.

Read more on NUE